Study Summary
This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD19 anti-CD20 Bispecific CAR-TBIOLOGICAL
patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Ludaopei Hospital | Sanhe | Hebei | China |